Business
Positive pre-clinical data on NXP002
Positive pre-clinical data on NXP002.
About this update from Nuformix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5045T\n Nuformix PLC\n 25 November 2021\n \n \n \n \n \n \n \n The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n \n \n Nuformix plc\n \n \n (\"Nuformix\" or the \"Company\")\n \n \n Positive pre-clinical data on NXP002\n \n \n Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, provides an update on its lead asset, NXP002, which it is currently developing as a potential novel treatment for Idiopathic Pulmonary Fibrosis (\"IPF\"). This update comes as a result of positive data received following initial pre-clinical studies. \n \n \n \n NXP002 is a repurposed, new form of tranilast, that the Company is developing in an inhaled formulation for direct delivery to the lungs. Nuformix has successfully performed a number of pre-clinical studies as planned to generate a robust data package. The studies completed of the data package thus far comprise of:\n \n - in vitro studies to demonstrate that NXP002 can be formulated in a formulation suitable for inhaled delivery by nebulisation; and\n - in vivo studies to look at the pharmacokinetics and pharmacodynamics of NXP002 in a pre-clinical species when inhaled.\n \n \n The in vitro studies demonstrated that it is feasible to formulate NXP002 into a simple and stable solution which has suitable properties for delivery via nebulisation. The data generated on these formulations also show that the drug can be efficiently delivered in the right particle size range for lung delivery using off-the-shelf and commonly used nebuliser devices. Thus, Nuformix believes that the delivery of NXP002 by nebulisation is feasible.\n \n \n \n \n \n The first of the in vivo studies evaluated the pharmacokinetics of NXP002 when delivered by nebulisation to rats. This study demonstrated that NXP002 can be efficiently delivered to the lung, achieving significant drug levels, whilst limiting systemic exposure compared to oral dosing.\n \n \n The second in vivo study evaluated the pharmacodynamics of NXP002 when deliver...